Breaking News, Financial News

Abbvie 4Q Results

Skyrizi and Rinvoq drive growth, offsetting 49% drop in Humira sales.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Image: Abbvie

AbbVie 4Q Revenues: $15.1 billion (+6%) 4Q Loss: $22 million (earnings were $822 million 4Q23) FY Revenues: $56.3 billion (+4%) FY Earnings: $4.3 billion (-12%) Comments: Global immunology portfolio sales in the quarter were $7.3 billion, up 5%. Humira sales were $1.7 billion, down 49%. Skyrizi sales were $3.8 billion, up 58% and Rinvoq sales were $1.8 billion, up 46%. Global oncology portfolio sales were $1.7 billion, up 12%. Imbruvica sales were $848 million, down 6%. Ve...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters